News & Analysis on Clinical Trial Services & Contract Research And Development
Researchers have published a new article launching a scathing attack on the growing incidence of healthcare professionals being paid exuberant 'finder's fees' whenever they recruit a patient onto a clinical trial.
Canada's National Centre for Foreign Animal Disease (NCFAD) has been designated as a reference lab for Bovine Spongiform Encephalopathy (BSE) by the World Organisation for Animal Health known as the OIE.
SuperArray Bioscience has made available a range of pathway-focused real-time PCR gene panels that allow scientists to use their real-time PCR instrument just like a microarray in the multiple stages involved in drug discovery and development.
As global contract research spending remains robust, business is booming for Pharmaceutical Product Development (PPD) as the US firm reported a surge in sales, profits and new business for its second quarter 2006.
Drug researchers have turned to an unusual source to boost the efficacy of a particular anticancer drug by investigating the properties of a mushroom that has been used for centuries in Eastern Asian medicine.
Cambrex's Q2 results show that the life sciences firm is slowly making a comeback after being crushed by a $140.3m (€116.7m) loss in Q4, however, it has failed to completely stem the bleed from its Biopharma unit, blamed for much of the company's woes.
Researchers have developed a new method by which cells can be glued to an exact position on a carrier.
More and more drugmakers are turning to health care companies not just for their drug delivery technologies but also for their regulatory and manufacturing expertise, asking them to take their product from early stages all the way to post-approval.
Are big pharma companies uninterested in supporting novel formulations, preferring to stick to low-risk drug delivery systems, or are they resourceful innovators that bring new technologies to the market? Two pharma grandees holding opposite views...
Aldevron has announced the expansion of its Genetic Immunisation and Antibody (GIA) facility to meet the increased demand of vaccine screening contracts.